Neglect Syndrome and the Spatial Attention Network
Introduction of Neglect Syndrome and the Spatial Attention Network
Neglect syndrome is a common neurological syndrome that mainly occurs after injury to the right hemisphere and is characterized by spatial and non-spatial defects. Neglect is not a single symptom, but a collection of uneven symptoms caused by discrete lesions in the right hemisphere. In patients with neglect syndrome, attention to contralateral events is significantly reduced, it showed unwillingness to shift their attention to the left, and unable to effectively find targets embedded in the left hemisphere. Side neglect syndrome is thought to reflect the damage of large-scale frontal and parietal lobe networks, and this network usually maintains the adaptive distribution of spatial attention. It is more likely to be a distributed cortical network spatial attention dysfunction, and it is not structural damage in a specific brain area.
Regulatory Mechanisms and Potential Targets
Most lesions of neglect syndrome are in the survey area of the right hemisphere, called the outer cortex. These include the inferior parietal lobule (IPL), the angular gyrus and the superior marginal gyrus, the temporal parietal junction (TPJ), the superior temporal gyrus (STG), and the frontal cortex, including the inferior frontal gyrus (IFG) and the middle frontal gyrus (MFG). On the other hand, neglect and/or spatial attention deficits are also associated with damage to the right dorsal cortex, including superior frontal gyrus/frontal eye field (SFG/FEF) and superior parietal lobe (SPL). In addition, some subcortical structures are also related to neglect, the thalamus and certain white matter, such as the upper longitudinal tract (SLF) II, SLF III and arcuate tract (AF), inferior longitudinal tract, inferior frontal occipital tract (IFOF) and extreme capsule (EmC).
Fig.1 Structural connectivity in the spatial attention network damaged in neglect patients. (Hattori, 2018)
Some current research results indicated that the choline system plays a role in guiding attention to discover and distinguish visual information, while the dopamine system is mainly related to the working memory process. However, the process of visual spatial attention and working memory is not completely separated, so the spatial attention network of neglect syndrome is also regulated by the interaction mechanism of the cholinergic system and dopamine.
Conventional Treatment of Neglect Syndrome
- Cueing
- Patching
- Drug therapy
Many clinical methods use clues to break neglect and play an effective role in the early stages of the disease or cases of closed head injuries.
When the irritation occurs in the opposing area, using a patch on the same diseased eye enhances the effect of the mound-like mechanism.
The results of the study show that cholinergic blockers reduce the cost of distracting attention, and norepinephrine reduces the alertness effect, indicating that drug treatment can be applied to neglect syndrome.
Creative Biolabs can provide you with acetylcholine blockers and dopamine receptor activators for neglect syndrome and spatial attention network research.
Product Name | Biological Activity | Target | Cat.NO. |
Donepezil hydrochloride | Inhibitor | Acetylcholinesterase | MOD2005ZP665 |
Homovanillic acid | Activator | Dopamine Receptor | MOD2005ZP223 |
Huperzine A | Inhibitor | Acetylcholine | NMO1120FY046 |
Duloxetine HCl | inhibitor | 5-HT-noradrenaline reuptake | NMO1120FY038 |
If You need any customized services or products, please feel free to contact us if you are interested or have any questions.
Reference
- Hattori, T.; et al. Structural connectivity in spatial attention network: reconstruction from left hemispatial neglect. Brain imaging and behavior. 2018, 12(2): 309-323.
- iNeuMab™ Anti-pTau Antibody (NRP-0422-P1719) (Cat#: NRP-0422-P1719)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P2275) (Cat#: NRP-0422-P2275)
- iNeuMab™ Anti-F-Spondin/SPON1 Antibody, Clone 3F4 (Cat#: NRZP-0822-ZP4740)
- iNeuMab™ Mouse Anti-LRP1 Monoclonal Antibody (CBP3363) (Cat#: NAB-0720-Z6479)
- iNeuMab™ Anti-ApoC3 BBB Shuttle Antibody (NRZP-1022-ZP3503) (Cat#: NRZP-1022-ZP3503)
- iNeuMab™ Anti-SEZ6 Antibody (NRP-0422-P515) (Cat#: NRP-0422-P515)
- iNeuMab™ Anti-GARP Antibody (NRP-0422-P1639) (Cat#: NRP-0422-P1639)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P1760) (Cat#: NRP-0422-P1760)
- iNeuMab™ Mouse Anti-SHANK3 Monoclonal Antibody (CBP929) (Cat#: NAB-0720-Z3477)
- iNeuMab™ Anti-Alpha Synuclein BBB Shuttle Antibody (NRZP-1022-ZP4050) (Cat#: NRZP-1022-ZP4050)
- Mouse Midbrain Dopaminergic Neuron Cell MN9D (Cat#: NCL2110P059)
- iNeu™ Human Schwann Cell (Cat#: NCL-2103-P63)
- Immortalized Human Cerebral Microvascular Endothelial Cells (Cat#: NCL-2108-P020)
- Human Retinal Epithelial Cell ARPE-19 (Cat#: NCL2110P069)
- Human Blood Brain Barrier Model (Cat#: NCL-2103-P187)
- Mouse Microglia from C57BL/6 (Cat#: NCL-21P6-082)
- Rat Schwann Cells RSC96, Immortalized (Cat#: NCL-2108P21)
- Rat Immortalized Retinal Muller Cell Line rMC-1 (Cat#: NCL-2106-S93)
- Rat Microglia Cell Line HAPI, Immortalized (Cat#: NCL2110P015)
- Green Fluorescent Tau cell Line (Cat#: NCL2110P219)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- AAV2/9-hEF1a-fDIO-eNpHR 3.0-mCherry-WPRE-pA (Cat#: NTA-2012-ZP78)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Rat Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) (NM_020093) ORF clone/lentiviral particle, Myc-DDK Tagged (Cat#: NEP-0621-R0041)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)